The FDA removed Eli Lilly’s (LLY) tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future. The regulatory body concluded that the shortage of tirzepatide medicines is now resolved. The stock is gaining in the pre-market hours in response to the encouraging news. Lilly markets tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), as Mounjaro for type II diabetes (T2D) and Ze ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.The Food and Drug Administration on Thursday said the active ingredient in Eli Lilly's weight loss drug Zepbound is no longer in shortage, a decision that will eventually bar compounding pharmacies from making cheaper, unbranded versions of the injection."FDA has determined that the shortage of tirzepatide injection products, which first began in December 2022, is resolved," the agency said in a letter ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Eli Lilly just gave investors several reasons to cheer.The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as glucagon-like peptide-1 (GLP-1) receptor agonists, blockbuster drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, and others are completely redefining how care is provided to patients with diabetes or in need of weight management.While Danish-based pharmaceutical company Novo Nordisk (NVO -1.90%) leads the GLP-1 market (thanks in large ...

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effective in doing that. The success of Ozempic and Wegovy has helped the company behind the products, Novo Nordisk (NVO -0.04%), become one of the most valuable healthcare stocks in the world. But in an increasingly co ...

Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake. A long streak doesn't necessarily make a dividend stock a good long-term buy. After all, those increases may only be modest, for the sake of keeping the streak going. And if a company increases its dividend by just one or two percentage points, that's not even going to offset inflation.What Eli Lilly (LLY -0.05%) is doing is far more impressive. The company has been increasing its di ...

China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024INDIANAPOLIS, Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's ...

Lilly just gave investors more reasons to cheer the company on.Pharmaceutical giant Eli Lilly (LLY -0.10%) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster diabetes and obesity care medications, Mounjaro and Zepbound.The excitement surrounding the weight loss market has fueled a stock-buying frenzy, propelling Lilly to a market capitalization of roughly $720 billion -- making it the most valuable pharmaceu ...

The international pharmaceutical giant Eli Lilly (NYSE: LLY ) has shown tremendous growth in the last few years. The growth happened thanks to its robust product portfolio, strategic acquisitions, and innovation-led initiatives. The company, which specializes in solving the world's most severe healthcare issues, isComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but ...

This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030INDIANAPOLIS and CAIRO, Dec. 17, 2024 /PRNewswire/ -- The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and ...